This factor induces the upregulation of miR-222-3p that, in turn, inhibits SRSF2 expression at a post-transcriptional level by binding its 3′ UTR, finally resulting in the aberrant expression of Vascular Endothelial Growth Factor A (VEGFA) isoforms in breast cancer [153]. The gene discussed is VEGFA; the disease is breast carcinoma.